- Home
- VIVS vs APRE Comparison
VIVS vs APRE Comparison
Compare VIVS & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- APRE
- Stock Information
- Founded
- VIVS 2007
- APRE 2006
- Country
- VIVS United States
- APRE United States
- Employees
- VIVS N/A
- APRE N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- VIVS Health Care
- APRE Health Care
- Exchange
- VIVS Nasdaq
- APRE Nasdaq
- Market Cap
- VIVS 8.1M
- APRE 8.3M
- IPO Year
- VIVS N/A
- APRE 2019
- Fundamental
- Price
- VIVS $2.28
- APRE $1.42
- Analyst Decision
- VIVS
- APRE Strong Buy
- Analyst Count
- VIVS 0
- APRE 1
- Target Price
- VIVS N/A
- APRE $20.00
- AVG Volume (30 Days)
- VIVS 104.1K
- APRE 139.7K
- Earning Date
- VIVS 11-12-2025
- APRE 11-07-2025
- Dividend Yield
- VIVS N/A
- APRE N/A
- EPS Growth
- VIVS N/A
- APRE N/A
- EPS
- VIVS N/A
- APRE N/A
- Revenue
- VIVS $142,000.00
- APRE $841,012.00
- Revenue This Year
- VIVS $42.38
- APRE N/A
- Revenue Next Year
- VIVS $15.42
- APRE N/A
- P/E Ratio
- VIVS N/A
- APRE N/A
- Revenue Growth
- VIVS 94.52
- APRE N/A
- 52 Week Low
- VIVS $1.41
- APRE $1.31
- 52 Week High
- VIVS $21.96
- APRE $5.00
- Technical
- Relative Strength Index (RSI)
- VIVS 38.84
- APRE 44.10
- Support Level
- VIVS $2.14
- APRE $1.43
- Resistance Level
- VIVS $2.44
- APRE $1.69
- Average True Range (ATR)
- VIVS 0.27
- APRE 0.10
- MACD
- VIVS -0.09
- APRE -0.01
- Stochastic Oscillator
- VIVS 10.00
- APRE 28.95
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.